Clipos™ COVID-19 Spike Ptotein (Delta Variant) mRNA Lipid Nanoparticles


Catalog:CDPM13

Unit Size:200 μL

INQUIRY Datasheet

Specifications
Description This product utilizes the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of the Delta variant spike protein (COVID-19) mRNA to a variety of mammalian cells, including cell cultures which may typically be prone to difficulties in expressing desired proteins. The lipid nanoparticles used are formulated with, SM-102, DSPC, cholesterol, and DMG-PEG2000 at optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. COVID-19 Spike Proteins are highly glycosylated and play a major role in penetrating and initiating infection in host cells by coronaviruses. Spike proteins utlize two subunits: S1 recognizes and binds to the host cell causing conformational change that will allow fusion of viral envelope and host cell membrane by S2. The Delta variant of this spike protein was first discovered in India in late 2020 and quickly became the most prevalent strain. Research suggests that changes to the spike protein may allow the Delta variant up to 50% more transmission than other COVID-19 variants. This ability has rendered the delta variant spike protein a candid vice for mRNA delivery. mRNA encapsulated in lipid nanoparticle, primarily in PBS (-ca, -mg). Dilute levels of: sodium acetate, ethanol, free mRNA & free lipids.
Lipid composition SM-102/DSPC/cholesterol/DMG-PEG2000
Encoding mRNA COVID-19 Spike protein (Delta variant)
In Vitro QC (Cell Types) HEK293S
Technology Applications Vaccine development
Storage Store at 4°C
Technical Notes Work with mRNA-LNP on ice. It is important to minimize the time that the product spends at room temperature; after handling product during experiments, return immediately to ice.
Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container; it is important not to spin for too long as this may rupture mRNA-LNP’s. Do not vortex.
mRNA-LNP products should only be handled with certified RNAase-free reagents and consumables; use of filtered pipette tips is highly recommended.
Usage 1. Prior to transfection, in a 12 well culture plate, plate your cells at [0.5E6 cells/mL] in a total of 1 mL per well. Ensure the cells you are using are viable and healthy. Try not to let your cells sit for longer than 5 minutes prior to transfection; cell clumping at the time of transfection may reduce transfection efficiency.
2. Briefly pipette mRNA-LNP solution up and down to resuspend. Add 20 uL of the mRNA-LNP mix dropwise directly to your 1 mL culture. Gently tilt plate back and forth to mix (not necessary if you are using cells which will be immediately placed back into a shaker). Place your transfected cells back into their original culture conditions.
3. Check cell expression by FACS at 24hr intervals after transfection.
*Note: This is a generalized protocol for transfection using mammalian cells. Transfection volume may be scaled down/up proportionately.
Related Products
Product Name Catalog Lipid composition Liposome Size Price
Clipos™ EGFP mRNA Lipid Nanoparticles CDPM01 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ mCherry mRNA Lipid Nanoparticles CDPM02 INQUIRY
Clipos™ mCherry-Luciferase mRNA Lipid Nanoparticles CDPM03 INQUIRY
Clipos™ Luciferase mRNA Lipid Nanoparticles CDPM04 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ CAS 9-RNA Lipid Nanoparticles-HA CDPM05 INQUIRY
Clipos™ ANTI-BCMA mRNA Lipid Nanoparticles CDPM06 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-CD19 mRNA Lipid Nanoparticles CDPM07 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Clipos™ ANTI-HER2 mRNA Lipid Nanoparticles CDPM08 SM-102/DSPC/cholesterol/DMG-PEG2000 INQUIRY
Products
Fill out the form below
to receive a quote

GET A QUOTE

  • (USA)
  • (Europe)
Cookie Policy | Privacy Policy | Copyright © 2024 CD Bioparticles. All rights reserved.
0
Inquiry Basket
Inquiry